Myriad Genetics Inc (MYGN)
15.12
-0.18
(-1.18%)
USD |
NASDAQ |
Nov 21, 16:00
15.12
0.00 (0.00%)
After-Hours: 20:00
Myriad Genetics Revenue (Quarterly): 213.30M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 213.30M |
| June 30, 2024 | 211.50M |
| March 31, 2024 | 202.20M |
| December 31, 2023 | 196.60M |
| September 30, 2023 | 191.90M |
| June 30, 2023 | 183.50M |
| March 31, 2023 | 181.20M |
| December 31, 2022 | 177.80M |
| September 30, 2022 | 156.40M |
| June 30, 2022 | 179.30M |
| March 31, 2022 | 164.90M |
| December 31, 2021 | 160.80M |
| September 30, 2021 | 167.30M |
| June 30, 2021 | 189.40M |
| March 31, 2021 | 173.10M |
| September 30, 2020 | 145.20M |
| June 30, 2020 | 93.20M |
| March 31, 2020 | 164.00M |
| December 31, 2019 | 195.10M |
| September 30, 2019 | 186.30M |
| June 30, 2019 | 215.40M |
| March 31, 2019 | 216.60M |
| December 31, 2018 | 216.80M |
| September 30, 2018 | 202.30M |
| June 30, 2018 | 193.90M |
| Date | Value |
|---|---|
| March 31, 2018 | 183.10M |
| December 31, 2017 | 187.90M |
| September 30, 2017 | 178.80M |
| June 30, 2017 | 157.80M |
| March 31, 2017 | 196.90M |
| December 31, 2016 | 196.50M |
| September 30, 2016 | 177.50M |
| June 30, 2016 | 173.10M |
| March 31, 2016 | 190.50M |
| December 31, 2015 | 193.30M |
| September 30, 2015 | 183.50M |
| June 30, 2015 | 189.90M |
| March 31, 2015 | 180.00M |
| December 31, 2014 | 184.40M |
| September 30, 2014 | 168.80M |
| June 30, 2014 | 188.75M |
| March 31, 2014 | 182.92M |
| December 31, 2013 | 204.06M |
| September 30, 2013 | 202.47M |
| June 30, 2013 | 174.15M |
| March 31, 2013 | 156.47M |
| December 31, 2012 | 149.14M |
| September 30, 2012 | 133.44M |
| June 30, 2012 | 132.96M |
| March 31, 2012 | 129.78M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
93.20M
Minimum
Jun 2020
213.30M
Maximum
Sep 2024
176.14M
Average
179.30M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| Boston Scientific Corp | 4.209B |
| ResMed Inc | 1.225B |
| Globus Medical Inc | 625.70M |
| Perspective Therapeutics Inc | -- |
| Electromed Inc | 14.67M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -22.10M |
| Total Expenses (Quarterly) | 231.10M |
| EPS Diluted (Quarterly) | -0.24 |
| Enterprise Value | 1.316B |
| Gross Profit Margin (Quarterly) | 70.23% |
| Profit Margin (Quarterly) | -10.36% |
| Earnings Yield | -8.60% |
| Normalized Earnings Yield | -7.562 |